| Application no. and date | 19716296.9 (espacenet) (Federated) (European Patent Register), 20190301 | | Patent/reg. no. and date | DK/EP 3758708, 20241127 | | Publication date | 20210106 | | Priority no. and date | US 201862636944 P, 20180301 | | EP pub. no. and date |
EP 3758708 20210106 | | Effective date | | | Applicant/owner | AstraZeneca AB,
151 85 Södertälje, SE | | Applicant ref. no. | 642196 | | Inventor | WIKSTRÖM, Håkan, c/o Astrazeneca R&D Gothernberg
431 83 Mölndal, SE,
LUDVIGSSON, Jufang Wu, c/o Astrazeneca R&D Gothernberg
431 83 Mölndal, SE,
ANDERSSON, Thomas, c/o Astrazeneca R&D Gothernberg
431 83 Mölndal, SE | | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB, GB | | Opponent | | | IPC Class | A61K 31/553 (2006.01) , A61P 11/06 (2006.01) | | Title | FARMACEUTISKE SAMMENSÆTNINGER, SOM OMFATTER (2S)-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-YL)PHENYL]ETHYL}-1,4-OXAZEPAN-2-CARBOXAMID | | Int. application no. | EP2019055138 | | Int. publication no. | WO2019166626 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
